Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Deutsche Bank AG

Deutsche Bank AG lifted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 1,007.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 296,015 shares of the company's stock after acquiring an additional 269,283 shares during the quarter. Deutsche Bank AG owned 0.46% of Mineralys Therapeutics worth $4,701,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. lifted its stake in shares of Mineralys Therapeutics by 297.5% during the 1st quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company's stock worth $25,000 after acquiring an additional 1,190 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Mineralys Therapeutics in the 4th quarter worth about $48,000. CWM LLC increased its stake in Mineralys Therapeutics by 59.3% in the 1st quarter. CWM LLC now owns 8,342 shares of the company's stock worth $132,000 after buying an additional 3,105 shares during the period. GAMMA Investing LLC increased its stake in Mineralys Therapeutics by 9,602.2% in the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock worth $140,000 after buying an additional 8,738 shares during the period. Finally, ProShare Advisors LLC purchased a new position in Mineralys Therapeutics in the 4th quarter worth about $128,000. 84.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MLYS shares. Jefferies Financial Group started coverage on shares of Mineralys Therapeutics in a research report on Tuesday, June 10th. They set a "hold" rating and a $15.00 target price on the stock. Wall Street Zen downgraded Mineralys Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Guggenheim set a $48.00 price objective on Mineralys Therapeutics and gave the stock a "buy" rating in a report on Wednesday, May 14th. Finally, HC Wainwright restated a "buy" rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research note on Wednesday, August 13th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Mineralys Therapeutics has an average rating of "Moderate Buy" and an average price target of $32.25.

Mineralys Therapeutics Stock Up 7.0%

Shares of Mineralys Therapeutics stock traded up $1.01 on Wednesday, reaching $15.48. The stock had a trading volume of 1,099,870 shares, compared to its average volume of 882,633. The company has a 50 day moving average price of $14.00 and a 200 day moving average price of $13.61. Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $18.38. The stock has a market capitalization of $1.03 billion, a P/E ratio of -4.35 and a beta of -0.29.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.12. On average, analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Insider Transactions at Mineralys Therapeutics

In other news, CFO Adam Scott Levy sold 59,925 shares of the stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $14.76, for a total value of $884,493.00. Following the sale, the chief financial officer owned 132,934 shares in the company, valued at $1,962,105.84. This represents a 31.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Malcom Rodman sold 11,365 shares of the stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $12.93, for a total transaction of $146,949.45. Following the completion of the sale, the insider owned 92,891 shares in the company, valued at $1,201,080.63. The trade was a 10.90% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 123,051 shares of company stock worth $1,776,262. Insiders own 33.24% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.